EnVivo raised $24 million from the sale of Series C Convertible Preferred Stock and Warrants to Fidelity Biosciences

Neurological-drug developer EnVivo Pharmaceuticals received $24 million in a series C round, bringing EnVivo’s total venture financing to nearly $60 million. The big spender is Fidelity Biosciences, which invested $24 million in exchange for Series C Convertible Preferred Stock and Warrants. Envivo’s other investors include BCM Technologies, Cogene Ventures, and NeuroVentures Capital. Alan Fullerton, who advised Envivo on the deal commented, “The investment from Fidelity provides EnVivo with the capital it will need to develop several new therapies.”

About Mirus Capital Advisors

Mirus Capital Advisors provides investment banking solutions to corporate clients in technology, business services, manufacturing, consumer products, health care, and the resort & hospitality industry. Since 1987, Mirus has provided corporate finance advisory services on engagements including mergers, acquisitions, divestitures, recapitalizations, and valuations. For additional information, visit www.merger.com.